Search results
Showing 121 to 135 of 204 results for lymphoma
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
Discontinued Reference number: GID-TA10140
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued Reference number: GID-TA10480
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
Awaiting development Reference number: GID-TA11590 Expected publication date: TBC
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]
Discontinued Reference number: GID-TA11173
Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.
View recommendations for HTG254Show all sections
Sections for HTG254
Discontinued Reference number: GID-TA10437
Awaiting development Reference number: GID-TA11050 Expected publication date: TBC
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Discontinued Reference number: GID-TA10750
After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.
Awaiting development Reference number: GID-TA11849 Expected publication date: TBC
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
In development Reference number: GID-TA11749 Expected publication date: 10 June 2027